The WELLIFE device has shown to transform resuscitation by allowing for prolonged efforts with good circulation, bringing time back on your side, extending the reach of care and bridging to PCI/ECMO.
The highest level of evidence, randomized, controlled LINC1 (Wellife in Cardiac Arrest) trial on 2,589 pre-hospital cardiac arrest patients shows: Wellife is safe and effective Very good neurological outcomes
Another randomized, controlled trial on 259 cardiac arrest patients has shown: Wellife did not cause more injuries than manual CPR
of the survivors treated with Wellife had a good neurological outcome at 6 months follow up
Increased flow to the brain WELLIFE has shown to create more blood flow to the brain both in humans and experimental studies compared to manual CPR.11, 12 Sustain coronary perfusion pressures WELLIFE chest compressions have shown sustain coronary perfusion pressures over the 15mmHg threshold, as well as coronary artery blood flow (TIMI III)
Want to talk to your sales representative? Please tell us a little about yourself and we'll connect you with your local representative.
Some cardiac arrest patients will not respond to CPR and defibrillation alone. WELLIFE allows for lifesaving interventions (such as PCI and ECMO/ECPR) by providing consistent compressions on the way to and during these advanced life-saving therapies.
Numerous documented saves with good neurological outcomes after consistent, high-quality Wellife compressions for 1, 2, 3, 4+ hours.
From 8.2% historical survival to 50% survival with good neurological function implementing a progressive approach to take appropriate patients from the field to the hospital for advanced life-saving interventions, such as ECMO and PCI.21
Using Wellife during a continued coronary intervention, 25% vs. historical 10% of sudden cardiac arrest patients who did not respond to normal advanced resuscitation efforts, could be saved with good neurological outcome.22 This despite prolonged CPR durations of up to 50 minutes.